Optimist Retirement Group LLC Has $241,000 Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Optimist Retirement Group LLC reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,005 shares of the medical equipment provider’s stock after selling 219 shares during the period. Optimist Retirement Group LLC’s holdings in Lantheus were worth $241,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Silverberg Bernstein Capital Management LLC grew its stake in Lantheus by 0.4% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after purchasing an additional 100 shares in the last quarter. Moody National Bank Trust Division raised its holdings in shares of Lantheus by 1.1% during the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after buying an additional 162 shares in the last quarter. Shaker Investments LLC OH raised its holdings in shares of Lantheus by 0.7% during the 1st quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock worth $1,740,000 after buying an additional 182 shares in the last quarter. NBC Securities Inc. raised its holdings in shares of Lantheus by 28.4% during the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock worth $53,000 after buying an additional 191 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. JMP Securities reduced their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Leerink Partners increased their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. B. Riley raised their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Truist Financial dropped their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Lantheus Trading Up 2.5 %

Shares of Lantheus stock opened at $108.14 on Thursday. The company has a market capitalization of $7.50 billion, a P/E ratio of 16.51 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The company has a fifty day moving average of $106.08 and a 200 day moving average of $83.62. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The firm’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.40 earnings per share. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Insider Activity

In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Mary Anne Heino sold 10,481 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the sale, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,852 shares of company stock worth $3,922,001. Corporate insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.